Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.…
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
Cuprina Holdings (Cayman) (NASDAQ: CUPR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 1.410 USD on 20 November 2026, down 77.2% over 52 weeks. Its 52-week range is 1.397 USD to 14.80 USD, and it trades at the bottom of that range.
Its market capitalisation is 10.79M USD.
Cuprina Holdings (Cayman) reports return on equity of -92.4% and revenue up 267.4% year over year.
Its debt exceeds its cash by 208.93K SGD, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.